In KM12 colon cancer cells, the two compounds led to a decrease in tropomyosin 3 (TPM3)-TRKA fusion protein levels as well as a decrease in AGBL carboxypeptidase 4 (AGBL4)-TRKB and ETS variant TF 6 (ETV6)-TRKC fusion protein levels [47]. This evidence concerns the gene TPM3 and colonic neoplasm.